Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 20/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 20/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 20/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 20/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 12/20 | 0.52 |
| ▸ | TSHR | P16473 | 11/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 10/20 | 0.52 |
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | HPGD | P15428 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | CLK4 | Q9HAZ1 | 13/20 | 0.52 |
| ▸ | LMNA | P02545 | 10/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 8/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 5/20 | 0.49 |
| ▸ | CASP1 | P29466 | 2/20 | 0.49 |
| ▸ | CASP7 | P55210 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29550399 | 1.00 | CYP1A2 (0.52) | CYP1A2CYP3A4CYP2D6CYP2C19CYP2C9 | |
| SCHEMBL29550822 | 0.84 | NPC1 (0.45) | CYP1A2CYP3A4CYP2D6CYP2C19MAPT | |
| SCHEMBL20522311 | 0.84 | NPC1 (0.45) | CYP1A2CYP3A4CYP2D6CYP2C19MAPT | |
| SCHEMBL20522302 | 0.84 | SLC22A12 (0.42) | MAPTCLK4KDM4E | |
| SCHEMBL29550852 | 0.84 | SLC22A12 (0.42) | MAPTCLK4KDM4E | |
| SCHEMBL20522378 | 0.82 | QPCT (0.40) | MAPTCLK4KDM4E | |
| SCHEMBL29550661 | 0.82 | QPCT (0.40) | MAPTCLK4KDM4E | |
| SCHEMBL20522363 | 0.80 | MAPT (0.44) | ALDH1A1MAPTHPGDSMN1; SMN2CLK4 | |
| SCHEMBL22712388 | 0.80 | ACP1 (0.46) | ALDH1A1MAPTLMNA | |
| SCHEMBL29550590 | 0.80 | ACP1 (0.46) | ALDH1A1MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110719910-B | Novel inhibitors | 维沃里翁治疗股份有限公司 | 2023-07-21 | — | — | CN | claimed |
| US-11339152-B2 | Inhibitors | VIVORYON THERAPEUTICS N.V. | 2022-05-24 | — | — | US | claimed |
| US-20200377493-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2020-12-03 | — | — | US | claimed |
| EP-3601269-A1 | NOVEL INHIBITORS | Probiodrug AG (DE) | 2020-02-05 | — | — | EP | claimed |
| WO-2018178384-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2018-10-04 | — | — | WO | claimed |
| US-20260001873-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2026-01-01 | — | — | US | disclosed |
| US-12384772-B2 | Inhibitors | VIVORYON THERAPEUTICS N.V. (DE) | 2025-08-12 | — | — | US | disclosed |
| CN-117024352-A | Novel inhibitors | 维沃里翁治疗股份有限公司 | 2023-11-10 | — | — | CN | disclosed |
| CN-110719910-B | Novel inhibitors | 维沃里翁治疗股份有限公司 | 2023-07-21 | — | — | CN | disclosed |
| US-20220274977-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2022-09-01 | — | — | US | disclosed |
| US-11339152-B2 | Inhibitors | VIVORYON THERAPEUTICS N.V. | 2022-05-24 | — | — | US | disclosed |
| US-11339152-B2 | Inhibitors | VIVORYON THERAPEUTICS N.V. | 2022-05-24 | — | — | US | disclosed |
| US-20200377493-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2020-12-03 | — | — | US | disclosed |
| US-20200377493-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2020-12-03 | — | — | US | disclosed |
| EP-3601269-A1 | NOVEL INHIBITORS | Probiodrug AG (DE) | 2020-02-05 | — | — | EP | disclosed |
| WO-2018178384-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2018-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001873-A1 | NOVEL INHIBITORS | GLS, GLS2, SULT1E1 | CYP1A2 839/4885CYP3A4 632/4885CYP2D6 164/4885 |
| US-20200377493-A1 | NOVEL INHIBITORS | GLUL, GLS, QPCT | CYP1A2 723/4885CYP3A4 987/4885CYP2D6 347/4885 |
| US-11339152-B2 | Inhibitors | GLUL, QPCT, GLS | CYP1A2 714/4885CYP3A4 1145/4885CYP2D6 389/4885 |
| US-12384772-B2 | Inhibitors | GLS, QPCT, GLS2 | CYP1A2 744/4885CYP3A4 1109/4885CYP2D6 397/4885 |
| US-20220274977-A1 | NOVEL INHIBITORS | GLUL, GLS, QPCT | CYP1A2 733/4885CYP3A4 953/4885CYP2D6 358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.